#### Edgar Filing: CRITICAL THERAPEUTICS INC - Form 4

CRITICAL T Form 4 February 15, 2	HERAPEUTIC	S INC									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION							-	PPROVAL			
	UNITED	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287		
Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	er <b>STATEN</b> 5. Filed put s Section 170	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								January 31Expires:2005Estimated averageburden hours perresponse0.5	
(Print or Type R	esponses)										
1. Name and Ac EVNIN LUK	2. Issuer Name and Ticker or Trading Symbol CRITICAL THERAPEUTICS INC [CRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) C/O MPM A MANAGEM CLARENDO FLOOR	SSET	Middle) FTH	3. Date of (Month/Da 02/13/20	-	insaction			below)	e title 109 below) mer 10% Owne		
DOGTON	(Street)		ndment, Date Original h/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
BOSTON, M	1A 02116							Person	store than one to	eporting	
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ties Ac	quired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	) Execution any	emed on Date, if 'Day/Year)	3. Transactic Code (Instr. 8) Code V	Disposed (Instr. 3,	l (A) o l of (D	)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	02/13/2007			$J^{(1)}$	7,226	A A	\$ 0	7,226	D		
Common Stock								3,845,876	I	See Footnote	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of<br/>information contained in this form are not<br/>required to respond unless the formSEC 1474<br/>(9-02)

#### Edgar Filing: CRITICAL THERAPEUTICS INC - Form 4

# displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	3	Date	7. Title an Amount of Underlyin Securities (Instr. 3 a	of ng s	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	or Title Nu of	umber		

10% Owner

Director

#### **Reporting Owners**

**Reporting Owner Name / Address** 

EVNIN LUKE C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116

Former 10% Owner

Relationships

Officer

Other

### Signatures

/s/ Luke Evnin 02/15/2007

<u>\*\*</u>Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pro rata distribution of partnership interests from MPM Asset Management Investors 2001 LLC, of which the reporting person is a member.

The shares are held as follows: 2,592,891 by MPM BioVentures II-QP, L.P. ("BV II QP"), 286,133 by MPM BioVentures II, L.P. ("BV II"), 53,841 by MPM Asset Management Investors 2001 LLC ("AM 2001") and 913,011 by MPM BioVentures GmbH & Co.

(2) Parallel-Beteiligungs KG ("BV KG"). MPM Asset Management II, L.P. ("AM II GP") and MPM Asset Management II LLC ("AM II LLC") are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is a member of AM II LLC and AM 2001. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.